📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-14 19:35
444 analysed today
FollowTelegram
444
Today
149,845
All-time analysed
42,954
Positive
6,669
Negative
91,525
Neutral
8,629
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
45 announcements match the current filters (relevance ≥ 5).
Gujarat Kidney Submits Unaudited Standalone & Consolidated Q1 Results Ended June 30, 2026
Gujarat Kidney And Super Speciality Limited has submitted its unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026. The independent statutory auditor, Y. M. Shah & Co., has issued an unmodified limited review report confirming compliance with Ind AS 34. The detailed P&L table was not included in the review report extract, but the submission satisfies quarterly regulatory compliance under Regulation 33. Investors should review the complete financial table once fully accessible on the exchange.
Confidence: MEDIUM
What changedThe company completed its quarterly board review and submitted standalone and consolidated limited review reports for Q1 ended June 30, 2026.
Why it mattersProvides regular regulatory disclosure and confirms from independent auditors that interim financial statements carry no material misstatements.
Quarter ended: 30-06-2026Auditor report date: 14.08.2026Audit opinion type: Unmodified limited reviewPromoter holding: 71.45%
📅 Short termNeutral trading expected as the filing represents routine quarterly results compliance without immediate auditor qualifications.
📈 Long termLimited direct impact from the review report alone; long-term performance hinges on hospital bed additions, NABH-driven pricing power, and geographic diversification beyond Vadodara.
⚠ Risk flags
- High geographic concentration risk with operations focused in Vadodara, Gujarat
- Detailed profit and loss statement numbers omitted from the auditor report text extract
Key Highlights
Board approved unaudited standalone and consolidated financial results for Q1 ended June 30, 2026.
Statutory auditor Y. M. Shah & Co. issued a clean limited review report with no qualifications on August 14, 2026.
Compliance fulfilled under Regulation 33 of SEBI Listing Obligations and Disclosure Requirements.
Promoter shareholding stood stable at 71.45% as of the June 2026 quarter.
👀 What to Watch
Track the full quarterly financial tables on the exchange to assess revenue growth, bed occupancy, and operating margins compared to previous quarters.
KSL Q1 FY27 Results: Net Profit Grows 10.9% YoY to ₹67.61 Cr
Kalyani Steels Limited (KSL) reported a steady Q1 FY27 with standalone revenue from operations at ₹464.58 Cr, a 4.9% increase compared to ₹442.77 Cr in Q1 FY26. Net profit for the quarter rose 10.9% YoY to ₹67.61 Cr, up from ₹60.97 Cr. On a sequential basis, revenue and profit saw a slight decline of 4.1% and 4.8% respectively compared to the March 2026 quarter. The company maintained a stable EPS of ₹15.49 for the quarter.
Confidence: HIGH
What changedKSL has reported its first-quarter financial results for FY27, showing moderate year-on-year growth but a slight sequential dip in performance.
Why it mattersThe results demonstrate KSL's ability to maintain stable margins and profitability despite its high exposure (70-80%) to the cyclical automobile sector and reliance on group company orders.
Revenue (Q1 FY27): ₹464.58 CrNet Profit (Q1 FY27): ₹67.61 CrYoY Revenue Growth: 4.9%QoQ Revenue Growth: -4.1%EPS (Q1 FY27): ₹15.49
📅 Short termThe stock is likely to remain range-bound as the results are largely in line with expectations and show no major surprises in operational efficiency.
📈 Long termStructural growth depends on the successful execution of the massive Odisha expansion, which is significantly larger than the company's current net worth of ₹2,100 Cr.
⚠ Risk flags
- High client concentration (55-60% sales to group companies)
- Heavy dependence on the commercial vehicle industry (70-80% of portfolio)
- Raw material price volatility
Key Highlights
Standalone Revenue from Operations stood at ₹464.58 Cr, representing ~25% of TTM revenue.
Net Profit after tax increased to ₹67.61 Cr from ₹60.97 Cr in the year-ago period.
Earnings Per Share (EPS) for the quarter was ₹15.49, compared to ₹13.97 in Q1 FY26.
Raw material costs accounted for ₹239.58 Cr, approximately 51.6% of revenue from operations.
Consolidated results include a small contribution from subsidiary DGM Realties, which reported a net profit of ₹0.64 Cr.
👀 What to Watch
Monitor the execution timeline of the ₹11,750 Cr Odisha expansion project and the operationalization of incremental billet capacity by FY2027, which are critical for long-term growth.
Rs 10 Final Dividend: Kalyani Steels Sets July 31 as Record Date for FY26 Payout
Kalyani Steels has announced a final dividend of Rs 10 per share (200% of face value) for FY 2025-26, representing an estimated total payout of ~Rs 43.6 crore based on current market capitalization. The company has fixed July 31, 2026, as the record date for determining eligibility and the deadline for submitting tax-related documents. The dividend is scheduled for payment on September 4, 2026, subject to shareholder approval at the AGM on August 27, 2026. This communication specifically outlines TDS procedures, including a 10% withholding tax for resident individuals with a valid PAN.
Confidence: HIGH
What changedThe company has formalized the administrative timeline and tax withholding procedures for the FY 2025-26 final dividend previously recommended in May 2026.
Why it mattersThis is a routine but necessary administrative step for the distribution of profits to shareholders, confirming the record date and payout schedule.
Dividend per share: Rs 10Dividend Yield: 1.12%Record Date: July 31, 2026Payout Date: September 4, 2026TDS Rate (with PAN): 10%TDS Exemption Limit (Residents): Rs 10,000
📅 Short termThe stock is expected to trade ex-dividend around the record date of July 31, 2026. No significant price volatility is expected from this administrative update.
📈 Long termLimited; this is a routine annual dividend distribution reflecting the company's stable payout history.
Key Highlights
Final dividend of Rs 10 per equity share of Rs 5 face value (200%) recommended for FY 2025-26.
Record date for dividend eligibility and tax document submission is July 31, 2026.
Dividend payout date is scheduled for September 4, 2026, following the AGM on August 27, 2026.
TDS of 10% will be deducted for resident individuals with PAN if the total dividend exceeds Rs 10,000.
Non-resident shareholders can avail DTAA benefits by submitting a Tax Residency Certificate (TRC) and Form 41.
👀 What to Watch
Shareholders should ensure their PAN and bank account details are updated with their Depository Participant by July 31, 2026, to avoid a higher 20% TDS and ensure seamless electronic credit.
Rs 10 Dividend: Kalyani Steels Sets July 31, 2026, as Record Date
Kalyani Steels Limited has announced a final dividend of Rs 10 per equity share (200% of face value) for the financial year. The company has fixed July 31, 2026, as the record date to determine shareholder eligibility. This payout follows a steady financial performance in FY25, where the company recorded a net profit of Rs 256.25 Cr. The dividend is subject to approval at the upcoming 53rd Annual General Meeting on August 27, 2026.
Confidence: HIGH
What changedThe company has finalized the specific dates for its annual dividend distribution and the 53rd Annual General Meeting.
Why it mattersThe announcement confirms the timeline for cash returns to shareholders, reflecting a payout ratio of approximately 17% against TTM PAT of Rs 257 Cr.
Dividend per share: Rs 10Dividend Yield: 1.08%Record Date: July 31, 2026AGM Date: August 27, 2026Face Value: Rs 5
📅 Short termThe stock price is expected to adjust downwards by the dividend amount on the ex-dividend date, which typically precedes the record date.
📈 Long termLimited structural impact; the company's long-term trajectory remains dependent on the execution of its Rs 11,750 Cr Odisha expansion project.
Key Highlights
Dividend declared at Rs 10 per equity share of face value Rs 5
Record date for dividend eligibility is July 31, 2026
53rd Annual General Meeting scheduled for August 27, 2026
Dividend payment to be completed on or before September 4, 2026
Dividend yield stands at approximately 1.08% based on the current price of Rs 921.7
👀 What to Watch
Investors seeking the dividend must hold the shares in their demat account by the record date of July 31, 2026; watch for the ex-dividend price adjustment usually occurring one session prior.
Kalyani Steels Resumes Hospet Plant Operations Following CPCB Revocation
Kalyani Steels Limited (KSL) has resumed manufacturing operations at its primary facility in Hospet, Karnataka, as of July 17, 2026. This follows a brief four-day shutdown triggered by a closure order from the Central Pollution Control Board (CPCB) on July 13, 2026. The CPCB conditionally revoked the order on July 16, 2026, after reviewing the company's compliance measures. Given the plant's 700,000 MTPA capacity, the quick resumption prevents a significant impact on the company's TTM revenue of ₹1,846 Cr.
Confidence: HIGH
What changedThe company's main manufacturing plant has returned to operational status after a temporary regulatory shutdown.
Why it mattersThe Hospet plant is KSL's core asset; a prolonged shutdown would have jeopardized its ability to service major OEM clients like Tata Motors and Maruti Suzuki, who rely on its specialty steel.
Closure Duration: 4 daysInstalled Capacity: 700,000 MTPATTM Revenue: ₹1,846 CrRevocation Date: July 16, 2026
📅 Short termThe resumption is a relief for the stock, as it eliminates the immediate uncertainty regarding production and revenue for the current quarter.
📈 Long termThe event highlights regulatory oversight risks; however, the quick resolution suggests the company has the internal systems to address compliance issues rapidly.
⚠ Risk flags
- Regulatory compliance risk
- Potential for future CPCB intervention if conditions are not met
Key Highlights
Manufacturing operations resumed on July 17, 2026, at the Hospet facility.
The CPCB issued a conditional revocation of its closure order via a letter dated July 16, 2026.
The plant was previously ordered to close on July 13, 2026, resulting in a 4-day operational halt.
The Hospet facility represents the company's total installed capacity of 700,000 MTPA.
KSL is now in the process of meeting specific CPCB conditions within a defined timeline.
👀 What to Watch
Investors should monitor future filings for confirmation that all CPCB-mandated conditions have been met to avoid further regulatory risk. The short duration of the shutdown suggests minimal impact on quarterly production volumes.
CPCB directs closure of 0.7 MTPA Hospet plant; key facility for Kalyani Steels
Kalyani Steels (KSL) has received a direction from the Central Pollution Control Board (CPCB) to close operations at its primary manufacturing plant in Hospet, Karnataka. The order, received on July 7, 2026, cites alleged violations of the Environment (Protection) Act, 1986. This facility represents the company's entire current installed capacity of 700,000 MTPA, which generated TTM revenue of ‡1,846 Cr. While KSL claims to have already complied with the issues and is seeking revocation, any prolonged shutdown would severely impact production and supply to major OEM clients.
Confidence: HIGH
What changedThe CPCB has issued a formal closure notice for KSL's main operational plant due to environmental non-compliance allegations.
Why it mattersThe Hospet plant is the core revenue-generating asset for KSL; a shutdown directly threatens its ability to service its 70-80% auto-sector client base and impacts its ‡257 Cr TTM PAT.
Current Installed Capacity: 700,000 MTPATTM Revenue at Risk: ‡1,846 CrCompliance Deadline: 30 daysNotice Receipt Date: July 7, 2026
📅 Short termExpect negative pressure on the stock as the market prices in the risk of a total operational halt at the company's only active plant.
📈 Long termWhile the company is expanding in Odisha (‡11,750 Cr), the Hospet plant remains the bridge to that future; regulatory hurdles here could signal higher compliance costs or execution risks for future projects.
⚠ Risk flags
- Operational shutdown
- Regulatory non-compliance
- Client supply disruption
Key Highlights
CPCB direction dated July 3, 2026, orders closure of the Hospet Road plant in Karnataka.
The plant has an installed capacity of 700,000 MTPA (0.7 MTPA), KSL's only operational site.
Company must submit notarized compliance to the CPCB within 30 days of receipt.
Facility serves critical automotive OEMs including Tata Motors, Maruti Suzuki, and Mahindra & Mahindra.
Financial impact is currently not ascertainable but involves a significant portion of ‡1,846 Cr TTM revenue.
👀 What to Watch
Monitor the timeline for the CPCB's revocation of the closure order and check for any production halt announcements in the coming days. Investors should watch for the 30-day compliance submission and subsequent regulatory feedback.
₹19.84 Cr Acquisition: GKSL to Acquire 51% Stake in UAE-based Blue Tree Clinics LLC
Gujarat Kidney And Super Speciality Limited (GKSL) has entered into a Share Purchase Agreement to acquire a 51% majority stake in Blue Tree Clinics LLC, a Dubai-based polyclinic, for ₹19.84 crore. This acquisition marks a significant strategic shift, moving the company beyond its 100% geographic concentration in Vadodara, Gujarat, into the UAE market. The target entity is profitable, reporting a net profit of 3.14 million AED (~₹7.1 crore) on a revenue of 10.54 million AED (~₹23.9 crore) for FY 2025. The acquisition cost of ₹19.84 crore is substantial, representing approximately 153% of GKSL's reported Dec 2025 quarterly revenue of ₹12.93 crore.
Confidence: HIGH
What changedGKSL is transforming from a regional, kidney-focused hospital in Vadodara to an international healthcare provider with a presence in Dubai and a broader range of medical services.
Why it mattersThis acquisition significantly scales the business, as the target's annual revenue is nearly half of GKSL's estimated annual run rate. It also mitigates the risk of 100% geographic concentration in Gujarat by entering the high-margin UAE healthcare market.
Acquisition Cost: ₹19,83,64,500Stake Acquired: 51%Target Revenue (FY25): 10,538,978 AEDTarget Net Profit (FY25): 3,138,809 AEDAcquisition Cost vs Dec-25 Qtr Revenue: 153.4%Completion Timeline: 50 days
📅 Short termThe stock is likely to react positively to the international expansion and the acquisition of a profitable entity with high margins.
📈 Long termIf successfully integrated, this provides a structural growth lever and diversifies the company's revenue streams away from pure nephrology into high-demand cosmetic and dental services.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Integration risk in a foreign jurisdiction (UAE)
- Diversification into unrelated medical fields (Cosmetic/Dental)
- Variation in IPO objects suggests a shift from original business plans
Key Highlights
Acquisition of 51% stake in UAE-based Blue Tree Clinics LLC for a cash consideration of ₹19,83,64,500
Target entity reported FY 2025 Gross Revenue of 10,538,978 AED and Net Profit of 3,138,809 AED
The acquisition is expected to be completed within a maximum period of 50 days in two tranches
Diversifies service offerings into Plastic Surgery, Laser Cosmetic, Dental, and Chiropractic care
Board approved a Postal Ballot for a Special Resolution to vary the 'Objects of IPO', likely to fund this acquisition
👀 What to Watch
Monitor the upcoming Postal Ballot for details on how IPO proceeds are being reallocated for this acquisition. Investors should also track the 50-day completion timeline and the subsequent impact on consolidated margins given the target's ~30% net profit margin.
GKSL to Acquire 51% Stake in UAE-based Blue Tree Clinics for ₹19.84 Crore
Gujarat Kidney And Super Speciality Limited (GKSL) has announced a major international expansion by acquiring a 51% stake in Blue Tree Clinics LLC, a Dubai-based polyclinic, for ₹19.84 crore. The target entity specializes in plastic surgery, dental, and cosmetic services, reporting a FY 2025 revenue of 10.54 million AED (~₹24 cr) and a net profit of 3.14 million AED (~₹7.1 cr). This acquisition is significant as the cost represents approximately 153% of GKSL's Dec 2025 quarterly revenue of ₹12.93 crore. Additionally, the company is seeking shareholder approval to vary its IPO objects and has appointed Dr. Paresh Dhoti as an Independent Director.
Confidence: HIGH
What changedGKSL is expanding from a single-location kidney speciality hospital in Vadodara to an international healthcare provider with a presence in the UAE and a broader service portfolio including cosmetic and dental care.
Why it mattersThe acquisition is a high-magnitude event relative to the company's current scale, potentially doubling its revenue base while reducing its 100% geographic concentration risk in Vadodara.
Acquisition Cost: ₹19.84 crStake Acquired: 51%Target FY25 Revenue: 10,538,978 AEDAcquisition Cost vs Dec 2025 Revenue: ~153%Target FY25 Net Profit: 3,138,809 AED
📅 Short termThe stock is likely to react positively to the inorganic growth news and international expansion, though the variation in IPO objects may raise questions.
📈 Long termIf integrated successfully, this marks a structural shift for GKSL into a multi-speciality healthcare group, though managing a UAE-based cosmetic clinic is a departure from their core kidney care expertise.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk in a new international geography (UAE)
- Business diversification risk (cosmetic/dental vs core nephrology)
- Uncertainty regarding the variation in IPO objects
Key Highlights
Acquisition of 51% majority stake in Blue Tree Clinics LLC, UAE, for a cash consideration of ₹19,83,64,500.
Target entity reported FY 2025 revenue of 10,538,978 AED and net profit of 3,138,809 AED.
The acquisition is expected to be completed within a maximum period of 50 days in two tranches.
Board approved a Postal Ballot to seek shareholder approval for variation in the Objects of the IPO.
Appointment of Dr. Paresh Dhoti, a dentist with 18 years of experience, as an Additional Independent Director for 5 years.
👀 What to Watch
Investors should monitor the successful completion of the UAE acquisition within the 50-day timeline and scrutinize the upcoming postal ballot for details on why IPO funds are being redirected.
GKSL Shareholders Approve Variation in IPO Proceeds Utilization with 99.99% Majority
Shareholders of Gujarat Kidney And Super Speciality Limited (GKSL) have passed a special resolution to vary the objects or terms of utilization of its Initial Public Offering (IPO) proceeds. The resolution received overwhelming support with 99.9995% of the votes cast in favor. A total of 56,894,985 votes were polled, representing a 72.16% turnout of the total 78,843,250 shares. This approval grants the management flexibility to redirect capital raised during the IPO toward revised corporate priorities.
Confidence: HIGH
What changedThe company has obtained formal shareholder approval to deviate from the original fund utilization plan outlined in its IPO prospectus.
Why it mattersChanging the use of IPO proceeds is a significant event that can alter the company's growth trajectory, debt profile, or expansion timelines compared to what was promised at the time of listing.
Total Votes Polled: 56,894,985Votes in Favor: 56,894,699Percentage in Favor: 99.9995%Promoter Votes: 56,333,900Public Turnout: 2.9992%
📅 Short termNeutral. The market will likely wait for specific disclosures on how the redirected funds are deployed before reacting significantly.
📈 Long termThe impact depends on whether the new allocation of funds generates higher returns than the original objects stated in the IPO prospectus.
⚠ Risk flags
- Deviation from original IPO prospectus
- High promoter concentration in voting results
- Low public shareholder participation
Key Highlights
Special resolution for variation in IPO objects passed with 99.9995% majority
Total votes polled reached 56,894,985 out of 78,843,250 total shares (72.16% turnout)
Promoter group provided 100% support with 56,333,900 votes in favor
Public non-institutional participation was low at 2.99% of their total holding
Only 286 votes were cast against the resolution across all categories
👀 What to Watch
Investors should review the specific details of the 'variation' mentioned in the May 28, 2026 notice to understand exactly how the capital is being redirected and if it aligns with the company's kidney-care growth strategy.
Kalyani Steels Appoints Former EIL CMD Vartika Shukla as Independent Director for 5 Years
Kalyani Steels has appointed Ms. Vartika Shukla, the former Chairman & Managing Director of Engineers India Limited (EIL), as an Additional Independent Director for a five-year term effective June 24, 2026. Ms. Shukla brings nearly 38 years of extensive experience in engineering consultancy and project management, having overseen business services worth over US $100 billion. Her background includes technical leadership in the energy and infrastructure sectors, supported by a B.Tech from IIT Kanpur and over 30 patents. This appointment is expected to significantly strengthen the board's strategic and technical oversight capabilities.
Key Highlights
Appointment of Ms. Vartika Shukla as Independent Director for a 5-year term until June 2031.
Ms. Shukla is the former CMD of EIL with nearly 38 years of experience in engineering and project management.
Managed high-value business services exceeding US $100 billion in the energy and infrastructure sectors.
Holds a B.Tech from IIT Kanpur and has co-authored over 30 patents in proprietary hardware and energy technologies.
👀 What to Watch
Investors should view this as a positive development for corporate governance and strategic planning. No immediate action is required, but the addition of high-caliber technical leadership is a long-term benefit for the company.
GKSL Seeks Shareholder Approval to Reallocate ₹37.76 Cr of IPO Proceeds
Gujarat Kidney And Super Speciality Limited (GKSL) has issued a postal ballot notice to vary the utilization of its IPO proceeds. The company intends to reallocate ₹37.76 Cr of unutilized funds, shifting focus from a specific Bharuch hospital project to broader healthcare expansion and inorganic growth. Notably, ₹19.02 Cr is being moved to the 'Funding inorganic growth and general corporate purposes' category, significantly increasing that bucket to ₹31.64 Cr. This move provides the management with greater flexibility for unidentified acquisitions and infrastructure upgrades across the parent and subsidiary companies.
Key Highlights
Seeking special resolution to reallocate ₹37.76 Cr of unutilized IPO proceeds
₹25.14 Cr originally for a Bharuch project is being repurposed for broader infrastructure and equipment
₹19.02 Cr transferred to 'Inorganic growth and general corporate purposes', bringing that total to ₹31.64 Cr
₹6.12 Cr specifically earmarked for modern equipment and facilities in parent and subsidiary units
Remote e-voting period for shareholders is set from June 5, 2026, to July 4, 2026
👀 What to Watch
Investors should monitor how the company utilizes the increased ₹31.64 Cr pool for inorganic growth, as the shift away from a specific project to unidentified acquisitions introduces execution risk. Evaluate if the new allocation toward general corporate purposes aligns with long-term value creation compared to the original IPO plan.
GKSL Reports 14% Revenue Growth in FY26; Proposes Variation in IPO Objects
Gujarat Kidney And Super Speciality Limited (GKSL) reported a steady financial performance for FY26, with revenue from operations rising to ₹40.10 crore from ₹35.17 crore in FY25. Net profit saw a modest increase of 8.7% to ₹9.90 crore, though EPS dipped slightly to 1.59 due to a significant expansion in the equity base. Notably, the company is seeking shareholder approval to vary the objects of its IPO proceeds and has deferred the appointment of a new CEO.
Key Highlights
Annual revenue from operations grew 14% YoY to ₹4,010.02 Lacs in FY26.
Net profit for the full year increased to ₹990.14 Lacs compared to ₹910.90 Lacs in FY25.
Total Equity surged significantly to ₹24,645.86 Lacs from ₹2,541.56 Lacs, reflecting post-IPO capital structure.
The Board has deferred the agenda for the appointment of a Chief Executive Officer (CEO).
A Postal Ballot will be conducted to seek approval for a Special Resolution regarding the variation in IPO objects.
👀 What to Watch
Investors should closely monitor the upcoming Postal Ballot details to understand why IPO funds are being redirected and track the deferred CEO appointment as a key leadership signal.
GKSL FY26 PAT Rises to ₹9.90 Cr; CEO Appointment Deferred; IPO Object Variation Proposed
Gujarat Kidney And Super Speciality Limited (GKSL) reported a 14% growth in annual revenue to ₹40.10 crore for FY26, with net profit increasing to ₹9.90 crore. The company has deferred the appointment of a CEO, leaving a key leadership position vacant for now. Notably, the board is seeking shareholder approval to vary the objects of its IPO, suggesting a change in how recently raised capital will be utilized. Total equity saw a massive jump to ₹246.46 crore, likely reflecting the impact of the IPO proceeds.
Key Highlights
Annual Revenue from Operations grew 14% YoY to ₹4,010.02 Lacs in FY26 compared to ₹3,516.70 Lacs in FY25.
Net Profit (PAT) for the year increased to ₹990.14 Lacs from ₹910.90 Lacs in the previous fiscal.
The Board of Directors deferred the agenda for the appointment of a Chief Executive Officer (CEO).
Proposed a Special Resolution via Postal Ballot for 'Variation in Objects of IPO', indicating a shift in capital allocation strategy.
Appointed Mr. Siddharth Atulbhai Shah as Internal Auditor and SPANJ & Associates as Secretarial Auditor for a 5-year term.
👀 What to Watch
Investors should seek clarity on the proposed 'Variation in Objects of IPO' as it indicates a change in the company's original growth or debt-repayment plans. Monitor the eventual CEO appointment to assess future leadership stability.
GKSL FY26 Net Profit Rises 8.7% to ₹9.9 Cr; Board to Vary IPO Objects
Gujarat Kidney And Super Speciality Limited (GKSL) reported a steady financial performance for FY26, with annual revenue reaching ₹40.10 crore compared to ₹35.17 crore in FY25. Net profit for the year grew to ₹9.90 crore, up from ₹9.11 crore in the previous fiscal. The company's balance sheet saw a massive expansion, with total assets jumping to ₹266.08 crore from ₹49.07 crore, primarily driven by post-IPO capital. However, the board has deferred the CEO appointment and is seeking shareholder approval to change the utilization of IPO proceeds.
Key Highlights
Annual Revenue from Operations grew 14% YoY to ₹4,010.02 Lacs in FY26.
Net Profit for the full year increased to ₹990.14 Lacs from ₹910.90 Lacs in FY25.
Total Assets surged to ₹26,607.67 Lacs, reflecting a significant increase in equity and investments post-listing.
Board proposed a Postal Ballot for a Special Resolution regarding 'Variation in Objects of IPO'.
The appointment of a new CEO has been deferred by the Board of Directors.
👀 What to Watch
Investors should closely monitor the details of the postal ballot regarding the variation in IPO objects to understand how the company plans to reallocate its capital. While earnings growth is stable, the deferred CEO appointment and change in fund utilization suggest a transitional phase for management.
GKSL to Deploy 100 AI-Powered Haemodialysis Machines; First 8 Units Live in 10 Days
Gujarat Kidney And Super Speciality Limited (GKSL) has announced a major capacity expansion by procuring 100 AI-enabled Haemodialysis machines. The first phase involves commissioning 8 units at its Godhra facility within 10 days, following successful technical inspections. This move integrates advanced AI technology for real-time patient data analysis, which is expected to improve clinical outcomes and operational efficiency. The remaining units will be deployed across the company's network in a phased manner to meet growing demand for renal care in Gujarat.
Key Highlights
Procurement of 100 AI-powered Haemodialysis machines to scale up renal care services
Phase 1 deployment of 8 machines at Gujarat Multi Speciality Hospital, Godhra, within 10 days
AI technology enables real-time decision support and early detection of intradialytic complications
Strategic rollout planned across the network to increase session capacity and regional reach
👀 What to Watch
Investors should monitor the execution of the phased rollout as it is likely to drive higher patient volumes and improve the company's competitive positioning in specialized renal care. The adoption of AI technology may also lead to better clinical reputations and potentially higher margins over time.
Kalyani Steels FY26 PAT at ₹2,551M; Recommends ₹10 Dividend per Share
Kalyani Steels reported a marginal increase in annual profit to ₹2,551.37 million for FY26, despite a 6.8% decline in annual revenue to ₹18,456.07 million. The Board recommended a final dividend of ₹10 per share (200%), maintaining a healthy payout to shareholders. Quarterly performance was weaker, with Q4 PAT falling to ₹710.25 million from ₹792.83 million year-on-year. The company also announced key leadership changes, including the appointment of a new CFO and an Independent Director.
Key Highlights
Annual Revenue from Operations decreased by 6.8% YoY to ₹18,456.07 million.
Full-year Profit After Tax (PAT) remained stable at ₹2,551.37 million compared to ₹2,530.34 million in FY25.
Recommended a dividend of ₹10 per equity share (200% of face value) for FY 2025-26.
Recorded an exceptional item of ₹79.26 million due to the financial impact of new Labour Codes.
Appointed Mr. Bantu Upendra Kumar Patro as Chief Financial Officer effective May 9, 2026.
👀 What to Watch
Investors should focus on the company's ability to maintain margins despite a dip in top-line growth. The steady dividend payout remains a positive for long-term holders, but operational efficiency under the new CFO should be monitored.
Kalyani Steels Declares ₹10 Dividend; FY26 Net Profit Stable at ₹2,551 Million
Kalyani Steels has recommended a final dividend of ₹10 per share for FY 2025-26, representing a 200% payout on face value. For the full year, the company reported a marginal 0.8% increase in Profit After Tax to ₹2,551.37 million, even as revenue from operations dipped by 6.8% to ₹18,456.07 million. The fourth quarter saw a contraction in both top-line and bottom-line performance compared to the previous year. Additionally, the company announced key leadership changes, including the appointment of a new CFO and an Independent Director.
Key Highlights
Recommended a final dividend of ₹10 per equity share of ₹5 each (200%) for FY 2025-26.
Full-year Revenue from Operations decreased by 6.8% to ₹18,456.07 million from ₹19,819.04 million.
Annual Profit After Tax (PAT) remained stable at ₹2,551.37 million versus ₹2,530.34 million in FY25.
Q4 FY26 PAT declined to ₹710.25 million compared to ₹792.83 million in the same quarter last year.
Appointed Mr. Bantu Upendra Kumar Patro as Chief Financial Officer effective May 9, 2026.
👀 What to Watch
While the consistent dividend provides a yield cushion, investors should be cautious about the declining revenue trend observed in FY26. Monitor the new management's strategy to address top-line growth and the impact of the ₹79.26 million exceptional labor code cost on future margins.
Kalyani Steels FY26 PAT at ₹2,551M; Recommends ₹10 Dividend per Share
Kalyani Steels reported a marginal increase in full-year standalone PAT to ₹2,551.37 million for FY26, despite a 6.8% decline in annual revenue to ₹18,456.07 million. The Board has recommended a final dividend of ₹10 per equity share (200% of face value). Quarterly performance showed pressure, with Q4 revenue dropping 11% YoY to ₹4,843.94 million. The company also announced the appointment of a new CFO and an Independent Director to strengthen its leadership team.
Key Highlights
Recommended a dividend of ₹10 per equity share (200%) for the financial year 2025-26.
Full-year FY26 Revenue from Operations stood at ₹18,456.07 million compared to ₹19,819.04 million in FY25.
Standalone Net Profit for the full year marginally increased to ₹2,551.37 million from ₹2,530.34 million.
Recognized an exceptional item of ₹79.26 million related to the financial impact of new Labour Codes.
Appointed Mr. Bantu Upendra Kumar Patro as Chief Financial Officer effective May 9, 2026.
👀 What to Watch
Investors should focus on the company's ability to maintain profitability and a healthy dividend payout despite a contraction in top-line growth. Monitor the new management's strategy for navigating revenue headwinds in the steel sector.
GKSL to Incorporate New Subsidiary for Bharuch Expansion and Appoints New CS
Gujarat Kidney And Super Speciality Limited (GKSL) has approved the incorporation of a Wholly Owned Subsidiary (WOS) to expand its healthcare footprint into the Bharuch district of Gujarat. The company received shareholder approval via postal ballot to utilize IPO funds for this healthcare expansion. Additionally, the board approved a voluntary revision of financial statements under Section 131 of the Companies Act, indicating a correction in previous reporting. Ms. Vishakha Mahesh Phadke has been appointed as the new Company Secretary and Compliance Officer to strengthen corporate governance.
Key Highlights
Approved incorporation of a Wholly Owned Subsidiary (WOS) with an initial nominal capital of ₹1,00,000.
Expansion targeted at Bharuch district, adding to existing presence in Vadodara, Dahod, Ahmedabad, and Godhara.
Shareholders passed a special resolution for interim utilization of IPO funds towards healthcare expansion.
Board approved voluntary revision of Financial Statements and Board's report under Section 131 of the Companies Act.
Appointment of Ms. Vishakha Mahesh Phadke as Company Secretary and Compliance Officer effective April 27, 2026.
👀 What to Watch
Investors should view the expansion into Bharuch as a positive growth move, but should also seek clarity on the reasons for the voluntary revision of financial statements. Monitor the timeline for the new subsidiary's operational launch, expected by the end of H1 FY 2026-27.
GKSL to Expand in Bharuch via New Subsidiary; Appoints New Company Secretary
Gujarat Kidney And Super Speciality Limited (GKSL) has approved the incorporation of a Wholly Owned Subsidiary (WOS) to expand healthcare services into Bharuch, Gujarat, with an initial capital of ₹1,00,000. Shareholders have also granted approval via Special Resolution for the interim utilization of funds toward healthcare expansion, aligning with the company's IPO objectives. Additionally, the board appointed Ms. Vishakha Mahesh Phadke as the new Company Secretary and Compliance Officer. The company is also proceeding with a voluntary revision of its financial statements and board report under Section 131 of the Companies Act.
Key Highlights
Approved incorporation of a 100% Wholly Owned Subsidiary for expansion into Bharuch District by H1 FY 2026-27.
Initial nominal capital for the new WOS set at ₹1,00,000 consisting of 10,000 equity shares.
Shareholders approved a Special Resolution for interim utilization of funds for healthcare expansion.
Ms. Vishakha Mahesh Phadke appointed as Company Secretary and Compliance Officer effective April 27, 2026.
Voluntary revision of Financial Statements and Board's report approved under Section 131 of the Companies Act.
👀 What to Watch
Investors should view the geographical expansion into Bharuch as a growth catalyst while monitoring the upcoming revised financial statements for any significant changes in historical data.
